ImmunoGen (IMGN) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.31 per share a year ago. These figures are ...

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has ...

ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Shares of ImmunoGen Inc. blasted off toward a record rally in very-active trading Wednesday, after the biotechnology company said a late-stage trial of its treatment for ovarian cancer produced ...

AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceutical’s entry into the market for ovarian cancer treatments. ImmunoGen Inc. developed the ...

After 41 years, ImmunoGen has scored its first approval for a solely owned drug. On Monday, the FDA signed off on Elahere to treat advanced ovarian cancer. Elahere (mirvetuximab soravtansine) becomes ...

Biotech stocks rose as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10 billion. Shares of ImmunoGen, which develops cancer treatments called antibody-drug conjugates, closed ...